{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:41:49Z","timestamp":1785872509111,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/hr.2016.158","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T07:11:17Z","timestamp":1480576277000},"page":"376-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial"],"prefix":"10.1038","volume":"40","author":[{"name":"Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Umemoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masunori","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"BFhr2016158_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","volume":"366","author":"LH Lindholm","year":"2005","unstructured":"Lindholm LH, Carlberg B, Samuelsson O . Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545\u20131553.","journal-title":"Lancet"},{"key":"BFhr2016158_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1291\/hypres.28.385","volume":"28","author":"JA Staessen","year":"2005","unstructured":"Staessen JA, Li Y, Thijs L, Wang JG . Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385\u2013407.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7326\/M14-0773","volume":"162","author":"J Sundstrom","year":"2015","unstructured":"Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B, Blood Pressure Lowering Treatment Trialists C. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015; 162: 184\u2013191.","journal-title":"Ann Intern Med"},{"key":"BFhr2016158_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/HJH.0b013e32834000be","volume":"29","author":"S Czernichow","year":"2011","unstructured":"Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B, Blood Pressure Lowering Treatment Trialists C. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29: 4\u201316.","journal-title":"J Hypertens"},{"key":"BFhr2016158_CR5","first-page":"1121","volume":"336","author":"F Turnbull","year":"2008","unstructured":"Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S, Blood Pressure Lowering Treatment Trialists C. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121\u20131123.","journal-title":"BMJ"},{"key":"BFhr2016158_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(14)62070-5","volume":"384","author":"J Sundstrom","year":"2014","unstructured":"Sundstrom J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, Baigent C, Emberson J, Rahimi K, MacMahon S, Patel A, Perkovic V, Turnbull F, Neal B, Blood Pressure Lowering Treatment Trialists C. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014; 384: 591\u2013598.","journal-title":"Lancet"},{"key":"BFhr2016158_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1023\/A:1007882624572","volume":"14","author":"S Koshy","year":"2000","unstructured":"Koshy S, Bakris GL . Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000; 14: 295\u2013301.","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFhr2016158_CR8","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/eurheartj\/ehr177","volume":"32","author":"PS Sever","year":"2011","unstructured":"Sever PS, Messerli FH . Hypertension management 2011: optimal combination therapy. Eur Heart J 2011; 32: 2499\u20132506.","journal-title":"Eur Heart J"},{"key":"BFhr2016158_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S, Japanese Society of Hypertension Committee for Guidelines for the Management of H. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253\u2013387.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR10","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA . 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159\u20132219.","journal-title":"Eur Heart J"},{"key":"BFhr2016158_CR11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jacc.2013.11.007","volume":"63","author":"AS Go","year":"2014","unstructured":"Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E . An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol 2014; 63: 1230\u20131238.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2016158_CR12","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F, Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527\u20131535.","journal-title":"Lancet"},{"key":"BFhr2016158_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1254\/jphs.DTJ05001X","volume":"100","author":"K Yao","year":"2006","unstructured":"Yao K, Nagashima K, Miki H . Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci 2006; 100: 243\u2013261.","journal-title":"J Pharmacol Sci"},{"key":"BFhr2016158_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1291\/hypres.28.331","volume":"28","author":"T Ogihara","year":"2005","unstructured":"Ogihara T, Matsuzaki M, Matsuoka H, Shimamoto K, Shimada K, Rakugi H, Umemoto S, Kamiya A, Suzuki N, Kumagai H, Ohashi Y, Takishita S, Abe K, Saruta T . The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res 2005; 28: 331\u2013338.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","volume":"29","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649\u20131659.","journal-title":"J Hypertens"},{"key":"BFhr2016158_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/hr.2011.216","volume":"35","author":"T Ogihara","year":"2012","unstructured":"Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res 2012; 35: 441\u2013448.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/hr.2013.100","volume":"36","author":"S Umemoto","year":"2013","unstructured":"Umemoto S, Ogihara T, Rakugi H, Matsumoto M, Kitagawa K, Shimada K, Higaki J, Ito S, Suzuki H, Ohashi Y, Saruta T, Matsuzaki M . Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial. Hypertens Res 2013; 36: 1088\u20131095.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/hr.2015.104","volume":"39","author":"S Umemoto","year":"2016","unstructured":"Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events CTG. Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial. Hypertens Res 2016; 39: 46\u201353.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR19","first-page":"3","volume":"32","author":"T Ogihara","year":"2009","unstructured":"Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension C. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3\u2013107.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/eurheartj\/eht407","volume":"35","author":"S Yusuf","year":"2014","unstructured":"Working Group on the Summit on Combination Therapy for CVD Working Group on the Summit on Combination Therapy for CVD Yusuf S Working Group on the Summit on Combination Therapy for CVD Attaran A Working Group on the Summit on Combination Therapy for CVD Bosch J Working Group on the Summit on Combination Therapy for CVD Joseph P Working Group on the Summit on Combination Therapy for CVD Lonn E Working Group on the Summit on Combination Therapy for CVD McCready T Working Group on the Summit on Combination Therapy for CVD Mente A Working Group on the Summit on Combination Therapy for CVD Nieuwlaat R Working Group on the Summit on Combination Therapy for CVD Pais P Working Group on the Summit on Combination Therapy for CVD Rodgers A Working Group on the Summit on Combination Therapy for CVD Schwalm JD Working Group on the Summit on Combination Therapy for CVD Smith R Working Group on the Summit on Combination Therapy for CVD Teo K Working Group on the Summit on Combination Therapy for CVD Xavier D . Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J 2014; 35: 353\u2013364.","journal-title":"Eur Heart J"},{"key":"BFhr2016158_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrcardio.2013.1","volume":"10","author":"G Parati","year":"2013","unstructured":"Parati G, Ochoa JE, Lombardi C, Bilo G . Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10: 143\u2013155.","journal-title":"Nat Rev Cardiol"},{"key":"BFhr2016158_CR22","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group SPRINT Research Group Wright JT Jr SPRINT Research Group Williamson JD SPRINT Research Group Whelton PK SPRINT Research Group Snyder JK SPRINT Research Group Sink KM SPRINT Research Group Rocco MV SPRINT Research Group Reboussin DM SPRINT Research Group Rahman M SPRINT Research Group Oparil S SPRINT Research Group Lewis CE SPRINT Research Group Kimmel PL SPRINT Research Group Johnson KC SPRINT Research Group Goff DC Jr SPRINT Research Group Fine LJ SPRINT Research Group Cutler JA SPRINT Research Group Cushman WC SPRINT Research Group Cheung AK SPRINT Research Group Ambrosius WT . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103\u20132116.","journal-title":"N Engl J Med"},{"key":"BFhr2016158_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/hr.2013.63","volume":"36","author":"H Rakugi","year":"2013","unstructured":"Rakugi H, Ogihara T, Umemoto S, Matsuzaki M, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. Hypertens Res 2013; 36: 947\u2013958.","journal-title":"Hypertens Res"},{"key":"BFhr2016158_CR24","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, group Vt. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022\u20132031.","journal-title":"Lancet"},{"key":"BFhr2016158_CR25","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","volume":"106","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, European Lacidipine Study on Atherosclerosis i. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422\u20132427.","journal-title":"Circulation"},{"key":"BFhr2016158_CR26","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","volume":"23","author":"LZY Liu","year":"2005","unstructured":"Liu LZY, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157\u20132172.","journal-title":"J Hypertens"},{"key":"BFhr2016158_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jch.12462","volume":"17","author":"SF Rimoldi","year":"2015","unstructured":"Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U . Efficacy and safety of calcium channel blocker\/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich) 2015; 17: 193\u2013199.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2016158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2016158","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2016158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:16:28Z","timestamp":1684430188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2016158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFhr2016158"],"URL":"https:\/\/doi.org\/10.1038\/hr.2016.158","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]},"assertion":[{"value":"31 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr SU was supported by research grants from Yamaguchi Prefecture, Japan, and KHK. Dr HR was supported by research grants from Daiichi Sankyo, Astellas Pharma, Dainippon Sumitomo Pharma, Eisai, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, Sanofi, Shionogi and Takeda Pharmaceutical. Dr SU received honoraria from Boehringer Ingelheim, Mochida Pharmaceutical, Takeda Pharmaceutical, Kowa Pharmaceutical, Novartis Pharma, Bayer Yakuhin and Daiichi Sankyo. Dr HR received honoraria from KHK, Astellas Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Takeda Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Shionogi, Taisho Toyama Pharmaceutical, and Bayer Yakuhin. Dr SU serves on an ad-hoc advisory board for Nippon Boehringer Ingelheim. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}